Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 19/20 | 0.76 |
| ▸ | HSP90AB1 | P08238 | 14/20 | 0.76 |
| ▸ | HSP90B1 | P14625 | 4/20 | 0.51 |
| ▸ | TRAP1 | Q12931 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1220121 | 1.00 | HSP90AA1 (0.76) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL1218933 | 0.96 | HSP90AA1 (0.69) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL19112807 | 0.92 | HSP90AA1 (0.65) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL1747367 | 0.88 | HSP90AA1 (0.62) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL1219717 | 0.86 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL1220332 | 0.86 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL1221137 | 0.84 | HSP90AA1 (0.75) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL1221140 | 0.84 | HSP90AA1 (0.75) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL1219824 | 0.82 | HSP90AA1 (0.93) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL1220475 | 0.81 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150328188-A1 | Combination Therapies for the Treatment of Proliferative Disorders | ORLEMANS EVERARDUS O (US) | 2015-11-19 | — | — | US | claimed |
| US-20200071308-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200071308-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2020-03-05 | — | — | US | disclosed |
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2017-09-14 | — | — | US | disclosed |
| EP-2380879-B1 | Tetrahydroindolone and tetrahydroindazolone derivatives | ESANEX INC (US) | 2017-07-12 | — | — | EP | disclosed |
| EP-2380879-B1 | Tetrahydroindolone and tetrahydroindazolone derivatives | ESANEX INC (US) | 2017-07-12 | — | — | EP | disclosed |
| US-9656956-B2 | Benzene, pyridine, and pyridazine derivatives | ESANEX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656956-B2 | Benzene, pyridine, and pyridazine derivatives | ESANEX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20150328188-A1 | Combination Therapies for the Treatment of Proliferative Disorders | ORLEMANS EVERARDUS O (US) | 2015-11-19 | — | — | US | disclosed |
| US-20090163493-A9 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | SERENEX, INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163493-A9 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | SERENEX, INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163493-A9 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | SERENEX, INC. | 2009-06-25 | — | — | US | disclosed |
| US-20080096887-A1 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | SERENEX, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096887-A1 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | SERENEX, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096887-A1 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | SERENEX, INC. | 2008-04-24 | — | — | US | disclosed |
| US-7358370-B2 | Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide | SERENEX, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358370-B2 | Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide | SERENEX, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358370-B2 | Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide | SERENEX, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-20060211737-A1 | Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide | ESANEX, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163493-A9 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | HSP90AA1, HSP90AB1, HSPA4 | HSP90AA1 1/4885HSP90AB1 2/4885HSP90B1 9/4885 |
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | CDK4, P2RX4, MKI67 | HSP90AA1 3912/4885HSP90AB1 3419/4885HSP90B1 3576/4885 |
| US-20080096887-A1 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | HSP90AA1, HSP90AB1, HSPA4 | HSP90AA1 1/4885HSP90AB1 2/4885HSP90B1 9/4885 |
| US-20150328188-A1 | Combination Therapies for the Treatment of Proliferative Disorders | HSP90AB1, HSP90B1, CDC37 | HSP90AA1 4/4885HSP90AB1 1/4885HSP90B1 2/4885 |
| US-20060211737-A1 | Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide | HSF1, HSPA4, HSP90AB1 | HSP90AA1 4/4885HSP90AB1 3/4885HSP90B1 23/4885 |
| US-20200071308-A1 | Benzene, Pyridine, and Pyridazine Derivatives | CDK4, P2RX4, MKI67 | HSP90AA1 3912/4885HSP90AB1 3419/4885HSP90B1 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.